LCTX
Price:
$0.8386
Market Cap:
$158.36M
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevi...[Read more]
Industry
Biotechnology
IPO Date
1992-03-05
Stock Exchange
AMEX
Ticker
LCTX
According to Lineage Cell Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -35.54%. This represents a change of 301.15% compared to the average of -8.86% of the last 4 quarters.
The mean historical ROE of Lineage Cell Therapeutics, Inc. over the last ten years is -45.10%. The current -35.54% ROE has changed -21.21% with respect to the historical average. Over the past ten years (40 quarters), LCTX's ROE was at its highest in in the September 2018 quarter at 38.99%. The ROE was at its lowest in in the March 2016 quarter at -157.69%.
Average
-45.10%
Median
-34.91%
Minimum
-174.75%
Maximum
28.47%
Discovering the peaks and valleys of Lineage Cell Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 299.02%
Maximum Annual ROE = 28.47%
Minimum Annual Increase = -143.14%
Minimum Annual ROE = -174.75%
Year | ROE | Change |
---|---|---|
2023 | -33.88% | -5.72% |
2022 | -35.93% | -14.07% |
2021 | -41.82% | 94.48% |
2020 | -21.50% | 105.37% |
2019 | -10.47% | -78.64% |
2018 | -49.01% | 299.02% |
2017 | -12.28% | -143.14% |
2016 | 28.47% | -116.29% |
2015 | -174.75% | 74.96% |
2014 | -99.88% | -66.31% |
The current ROE of Lineage Cell Therapeutics, Inc. (LCTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-37.21%
5-year avg
-28.72%
10-year avg
-45.10%
Lineage Cell Therapeutics, Inc.’s ROE is greater than MAIA Biotechnology, Inc. (-18051.81%), less than Armata Pharmaceuticals, Inc. (182.35%), less than Frequency Therapeutics, Inc. (187.90%), greater than Portage Biotech Inc. (-267.72%), less than AgeX Therapeutics, Inc. (172.71%), greater than Cadrenal Therapeutics, Inc. Common Stock (-93.71%), greater than ImmuCell Corporation (-16.35%), greater than Oxford Nanopore Technologies plc (-43.29%), greater than Replimune Group, Inc. (-52.15%), greater than Nuvectis Pharma, Inc. (-152.26%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Kronos Bio, Inc. (-68.82%), greater than Gossamer Bio, Inc. (-117.33%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Nuvation Bio Inc. (-98.79%), greater than Ovid Therapeutics Inc. (-33.40%), greater than NextCure, Inc. (-57.63%), less than Connect Biopharma Holdings Limited (7.21%), less than Spero Therapeutics, Inc. (20.70%), greater than Bolt Biotherapeutics, Inc. (-61.40%), less than Coherus BioSciences, Inc. (23.81%), greater than Gracell Biotechnologies Inc. (-37.20%),
Company | ROE | Market cap |
---|---|---|
-18051.81% | $68.85M | |
182.35% | $85.03M | |
187.90% | $10.94M | |
-267.72% | $5.25M | |
172.71% | $27.76M | |
-93.71% | $15.24M | |
-16.35% | $28.12M | |
-43.29% | $1.70B | |
-52.15% | $821.22M | |
-152.26% | $117.70M | |
-143.74% | $17.21M | |
-68.82% | $57.28M | |
-117.33% | $200.50M | |
-47.64% | $8.20M | |
-98.79% | $764.36M | |
-33.40% | $83.75M | |
-57.63% | $36.65M | |
7.21% | $66.30M | |
20.70% | $69.72M | |
-61.40% | $25.56M | |
23.81% | $77.19M | |
-37.20% | $989.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lineage Cell Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lineage Cell Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Lineage Cell Therapeutics, Inc.'s ROE?
How is the ROE calculated for Lineage Cell Therapeutics, Inc. (LCTX)?
What is the highest ROE for Lineage Cell Therapeutics, Inc. (LCTX)?
What is the 3-year average ROE for Lineage Cell Therapeutics, Inc. (LCTX)?
What is the 5-year average ROE for Lineage Cell Therapeutics, Inc. (LCTX)?
How does the current ROE for Lineage Cell Therapeutics, Inc. (LCTX) compare to its historical average?